Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-SARS-2-ST Inhalation Boost in SARS-CoV-2 Immunized Adults
NCT05226390Phase 1Terminated
- Sponsor
- Hannover Medical School
- Start
- Feb 2022
- Primary completion
- Nov 2023
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVA-SARS-2-ST in coronavirus disease 2019 (COVID-19), sponsored by Hannover Medical School. Primary endpoints: Adverse Events at day 28, Change from baseline of pulmonary function at day 140 and 3 more. Started Feb 2022; status: terminated.
02
Drugs
MVA-SARS-2-ST
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05226390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226390.